Does Kaiser Permanente Cover Ozempic?
The verdict
Conditional on most plans
Kaiser Permanente covers Ozempic for type 2 diabetes with prior authorization, typically Tier 3 on Kaiser's formulary. Kaiser Northwest applies the most restrictive step therapy in this cluster — maximum-tolerated metformin plus a documented SGLT-2 inhibitor trial (or intolerance/contraindication) — before approving Ozempic for T2D. Kaiser is a closed-network HMO: coverage applies only when a Kaiser physician prescribes within the Kaiser system. Ozempic is not covered for off-label weight loss under any Kaiser line of business.
Coverage is set by your specific plan and formulary. This is a research summary — always confirm with Kaiser Permanente using your member ID.
Key facts
Kaiser NW requires maximum-tolerated metformin AND a documented SGLT-2 inhibitor trial before approving Ozempic for T2D — the strictest step therapy of any insurer in the Ozempic cluster.
Kaiser Permanente Northwest, PA criteria for GLP-1 receptor agonists (reported via primary care PA pathway documentation)
Ozempic is FDA-approved for type 2 diabetes glycemic control, cardiovascular risk reduction in T2D patients with known CVD, and CKD progression in T2D patients — not for weight loss.
FDA drug labeling (semaglutide injection)
The IRA Maximum Fair Price for semaglutide under Medicare is $274 per 30-day supply, effective January 1, 2027 — a 71% discount off the CY2024 list price.
CMS, IRA Drug Price Negotiation Program, 2024
Medicare vs. commercial coverage
Whether Kaiser Permanente covers Ozempic depends heavily on which kind of plan you hold. They follow completely different rules — here's each one, side by side.
Medicare
Part D & Advantage plans
Medicare Advantage (Kaiser Senior Advantage): Ozempic is covered for type 2 diabetes with prior authorization under the Part D benefit. Tier 3 on the Kaiser formulary. PA requires a T2D diagnosis and step therapy — Kaiser NW's SGLT-2 step applies to Medicare Advantage enrollees as well; verify on your regional Kaiser Senior Advantage formulary. The 2026 Part D out-of-pocket cap is $2,100. Medicare beneficiaries cannot use the NovoCare savings card. The IRA Maximum Fair Price for semaglutide drops to $274 per 30-day supply on January 1, 2027. Ozempic is not covered for off-label weight loss under Medicare Part D benefit.
Commercial / Employer
Group & marketplace plans
Commercial/Employer and ACA/Individual (Kaiser HMO): Ozempic is covered for type 2 diabetes with prior authorization. Kaiser Northwest requires maximum-tolerated metformin PLUS a documented trial of (or intolerance/contraindication to) an SGLT-2 inhibitor (e.g., empagliflozin, dapagliflozin) before Ozempic PA will be approved — a two-step requirement stricter than almost all other insurers. Tier 3 on Kaiser's 2025 formulary. Commercially insured T2D patients may be eligible for the NovoCare Ozempic Savings Card ($25/fill, max $150/28-day) — verify eligibility, as Kaiser's closed-network pharmacy benefit may affect card usability. ACA plans follow the same closed-network PA criteria. Not covered for off-label weight loss. Medicaid: Kaiser operates Medicaid managed care in select states; covered for T2D with PA and nominal cost-share. Not covered for off-label weight loss. Note: Kaiser NW PA criteria vary by region — Kaiser Mid-Atlantic and California may use different step-therapy requirements; verify on your specific regional formulary.
The 4 boxes you must tick to get approved
Commercial plans that will consider Ozempic require prior authorization. Check off what applies to you to see how close you are — this is a guide, not a guarantee of approval.
Meet all 4 and you have a documented case for approval. Missing any one is the most common reason requests are denied.
Your cost, three ways
What Ozempic actually costs you swings enormously depending on how it's covered. Here's the realistic range.
Paying cash
~$1,028/month (Novo Nordisk published pricing, ~$1,027.51 for the 0.25/0.5 mg pen). NovoCare self-pay: ~$199/month intro price (first two fills through December 31, 2026), then ~$349/month (0.25/0.5/1 mg) or ~$499/month (2 mg).
List price with no coverage — before any manufacturer savings card.
With coverage
Commercial/ACA: Tier 3 cost-share on Kaiser's 2025 formulary; varies by plan design. Verify on your Kaiser plan. Medicare Advantage: Tier 3 cost-share; $2,100 Part D OOP cap 2026. IRA Maximum Fair Price of $274/30-day for semaglutide takes effect January 1, 2027. Medicaid: $0–$4 nominal cost-share where Kaiser operates Medicaid MCOs.
Typical monthly copay once prior authorization is approved.
Bridge program
NovoCare Ozempic Savings Card: commercially insured T2D patients may be eligible ($25/fill, max $150/28-day), but Kaiser's closed-network pharmacy benefit may limit card usability — verify with Kaiser pharmacy services. Medicare and Medicaid beneficiaries cannot use the card.
Reduced copay through the assistance program, where eligible.
All figures are estimates. Tier 3 cost-share varies by Kaiser plan design and region. Confirm exact cost-share with Kaiser member services or your regional Kaiser formulary.
Check YOUR exact coverage in 3 steps
General answers only get you so far. Here's how to confirm your own plan's decision in a few minutes.
- 1
Verify step-therapy requirements on your regional Kaiser formulary
Kaiser Permanente operates regionally (Northwest, Mid-Atlantic, California, etc.) and PA criteria can differ between regions. Kaiser NW requires the metformin + SGLT-2 two-step before Ozempic approval; other regions may use different criteria. Log in to your Kaiser member account at kp.org and check the formulary for your specific region, or call Kaiser member services to confirm the PA criteria that apply to your plan.
- 2
Ask your Kaiser physician to initiate the PA with full step-therapy documentation
Because Kaiser is a closed network, the PA must be initiated by your Kaiser physician. For Kaiser NW patients, the PA submission must document: (1) T2D diagnosis (ICD-10 E11.x), (2) maximum-tolerated metformin history or documented contraindication, and (3) SGLT-2 inhibitor trial history or documented intolerance/contraindication. Preparing all three before the PA submission will avoid back-and-forth with the PA reviewers.
- 3
Note the 2027 IRA price reduction and 2026 OOP cap
If you are enrolled in Kaiser Medicare Advantage, the IRA Maximum Fair Price for semaglutide drops to $274 per 30-day supply on January 1, 2027. In 2026, the $2,100 Part D OOP cap limits annual exposure. Contact Kaiser member services for a personalized cost estimate for your current plan year and region.
Options if Kaiser Permanente won't cover Ozempic
A denial isn't the end of the road. These are the paths people commonly explore next — discuss any of them with your prescriber.
Jardiance (empagliflozin) or Farxiga (dapagliflozin)
SGLT-2 inhibitors that serve as the required step-therapy predecessor to Ozempic at Kaiser NW. After a documented SGLT-2 trial or intolerance is on record, the Ozempic PA can proceed. Both are on Kaiser's formulary — verify tier via your regional Kaiser formulary.
Rybelsus (oral semaglutide)
Oral semaglutide for type 2 diabetes. Subject to the same T2D PA requirements at Kaiser. Also subject to IRA Maximum Fair Price of $274/30-day effective January 1, 2027 for Medicare patients.
Metformin (generic)
Tier 1 on Kaiser formularies. Required as the first step-therapy element before Ozempic PA at Kaiser NW (at maximum tolerated dose). Near-zero cost-share.
Compounded semaglutide (weight-loss seekers only)
For patients seeking semaglutide for weight management — Kaiser NW requires a failed Ozempic trial even before it will approve Wegovy for weight loss. For patients who want to avoid the full step-therapy process, compounded semaglutide from $49/mo is available at getcurex.com/cl/glp without insurance. See the offer section below for full disclaimers.
These options are listed for information only — your own clinician decides what is appropriate for you.
❓Frequently Asked Questions
No. Kaiser Permanente does not cover Ozempic for weight loss under any line of business. Ozempic is FDA-approved only for type 2 diabetes — not for weight management. No insurer covers Ozempic for off-label weight-loss use. At Kaiser NW, even Wegovy for weight loss requires a prior failed Ozempic trial for T2D before approval — meaning Ozempic is the diabetes prerequisite to Kaiser NW's weight-loss pathway, not a weight-loss drug itself.
Kaiser Northwest's PA criteria reflect its clinical protocol, not just a standard PBM formulary policy. Kaiser NW requires maximum-tolerated metformin plus a documented SGLT-2 inhibitor trial (empagliflozin, dapagliflozin) before approving Ozempic — a two-step requirement unique in this insurer cluster. SGLT-2 inhibitors have proven cardiovascular and renal benefits in T2D, and Kaiser NW's protocol positions them as a required prior therapy. If you cannot tolerate an SGLT-2 inhibitor, documenting that intolerance or contraindication clears this step.
The SGLT-2 step therapy requirement is confirmed for Kaiser Permanente Northwest. Kaiser Mid-Atlantic, California, and other regions may use different PA criteria — the SGLT-2 requirement is not confirmed as a universal Kaiser standard. Kaiser's regional structure means PA criteria can vary meaningfully between regions. Log in to your regional Kaiser member account or call member services to confirm the specific PA requirements that apply to your plan and region.
Yes. Kaiser is a closed-network HMO. Formulary coverage and prior authorization apply only when Ozempic is prescribed by a Kaiser physician within the Kaiser system. Out-of-network prescriptions are not covered under Kaiser's standard formulary benefit. If your diabetes specialist is outside the Kaiser network, you would need to either transfer care to a Kaiser physician or pay cash price for Ozempic without formulary coverage.
At Kaiser NW specifically, the two are directly linked in the PA pathway: Kaiser NW requires a failed adequate trial of Ozempic (for T2D) as a step before it will approve Wegovy for weight management. This means a T2D patient on Ozempic at Kaiser NW has already satisfied a prerequisite for the Wegovy weight-loss PA if they later pursue that route. This intra-molecule step-therapy requirement is unusual and not found at other insurers in this cluster.
Related Articles
Does Kaiser Permanente Cover Metformin? 2026 Guide
Yes — Kaiser Permanente covers metformin as a Tier 1 generic on its closed-network formulary at low or $0 cost-share. Verify at your Kaiser pharmacy.
Read moreDoes Kaiser Permanente Cover Eliquis? Coverage & Cost 2026
Yes — Kaiser covers Eliquis for AFib and VTE on its closed-network formulary. Must fill at Kaiser pharmacy. 2026 IRA price $231 for Senior Advantage.
Read moreDoes Kaiser Permanente Cover Vyvanse? | Curex
Kaiser Permanente covers Vyvanse on its closed formulary via Kaiser pharmacies — generic lisdexamfetamine preferred, brand non-preferred. 70 mg/day QL.
Read moreDoes Kaiser Permanente Cover Qsymia? 2026 | Curex
Kaiser's closed HMO limits Qsymia access; Medi-Cal excluded weight-loss drugs in 2026. Engage cash program ~$89/mo; generic launched 2025.
Read moreDoes Kaiser Permanente Cover Cialis? 2026 | Curex
Kaiser Permanente does not cover Cialis for ED — Medicare Part D bars it by law and commercial plans exclude it. Generic tadalafil IS covered for BPH.
Read moreDoes Kaiser Permanente Cover Victoza? 2026 Generic Guide | Curex
Kaiser covers Victoza for type 2 diabetes with prior auth, not weight loss. Generic liraglutide substitution is common. Saxenda is the weight-loss version.
Read moreInsurance won't cover Ozempic for weight loss — here's a path that doesn't need it
Kaiser NW covers Ozempic for type 2 diabetes — not for weight loss. For weight-loss access at Kaiser NW, even Wegovy requires a prior Ozempic failure, creating a multi-step barrier. Patients who want semaglutide for weight management without navigating Kaiser's step-therapy protocols can access compounded semaglutide from $49/mo at getcurex.com/cl/glp — no insurance, no prior authorization needed. Compounded semaglutide is not the same medication as Ozempic or Wegovy. Compounded tirzepatide is also available from $149/mo. Prescription required, subject to provider review.
- Medication + free shipping
- 24/7 provider access
- Medical intake & prescription review
Compounded semaglutide and tirzepatide are not the same medications as Ozempic and are not branded or FDA-approved products. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.
This content is for informational purposes only and does not constitute medical, financial, or insurance advice. Coverage rules, prior-authorization criteria, and copay amounts change frequently and vary by plan, formulary tier, and effective date — always verify current benefits directly with Kaiser Permanente before making any decision. Consult a licensed healthcare provider and your plan administrator for guidance specific to your situation. Curex offers compounded semaglutide and tirzepatide, which are not the same medications as Ozempic and are not branded or FDA-approved products; prescription required, subject to provider review. Compounded medications have not been approved by the FDA and the FDA has not evaluated their safety or efficacy.